BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 16491631)

  • 1. Targeting epigenetic changes in acute myeloid leukemia.
    Blum W; Marcucci G
    Clin Adv Hematol Oncol; 2005 Nov; 3(11):855-65, 882. PubMed ID: 16491631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute myeloid leukemia: therapeutic impact of epigenetic drugs.
    Altucci L; Clarke N; Nebbioso A; Scognamiglio A; Gronemeyer H
    Int J Biochem Cell Biol; 2005 Sep; 37(9):1752-62. PubMed ID: 15964234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic mechanisms in AML - a target for therapy.
    Oki Y; Issa JP
    Cancer Treat Res; 2010; 145():19-40. PubMed ID: 20306243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging treatments in acute myeloid leukaemia.
    Kell J
    Expert Opin Emerg Drugs; 2004 May; 9(1):55-71. PubMed ID: 15155136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitors as anti-neoplastic agents.
    Batty N; Malouf GG; Issa JP
    Cancer Lett; 2009 Aug; 280(2):192-200. PubMed ID: 19345475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic alterations and cancer: new targets for therapy.
    Allen A
    IDrugs; 2007 Oct; 10(10):709-12. PubMed ID: 17899489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome.
    Maslak P; Chanel S; Camacho LH; Soignet S; Pandolfi PP; Guernah I; Warrell R; Nimer S
    Leukemia; 2006 Feb; 20(2):212-7. PubMed ID: 16357841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
    Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis.
    Wang GG; Cai L; Pasillas MP; Kamps MP
    Nat Cell Biol; 2007 Jul; 9(7):804-12. PubMed ID: 17589499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic regulation of airway inflammation.
    Adcock IM; Tsaprouni L; Bhavsar P; Ito K
    Curr Opin Immunol; 2007 Dec; 19(6):694-700. PubMed ID: 17720468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenome: a new target in cancer therapy.
    Giacinti L; Vici P; Lopez M
    Clin Ter; 2008; 159(5):347-60. PubMed ID: 18998037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
    Zhong S; Fields CR; Su N; Pan YX; Robertson KD
    Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A distinct epigenetic signature at targets of a leukemia protein.
    Rossetti S; Hoogeveen AT; Liang P; Stanciu C; van der Spek P; Sacchi N
    BMC Genomics; 2007 Feb; 8():38. PubMed ID: 17266773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic interplay between histone modifications and DNA methylation in gene silencing.
    Vaissière T; Sawan C; Herceg Z
    Mutat Res; 2008; 659(1-2):40-8. PubMed ID: 18407786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA methylation as a pathogenic event and as a therapeutic target in AML.
    Schoofs T; Müller-Tidow C
    Cancer Treat Rev; 2011; 37 Suppl 1():S13-8. PubMed ID: 21612874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic targets in hematopoietic malignancies.
    Claus R; Lübbert M
    Oncogene; 2003 Sep; 22(42):6489-96. PubMed ID: 14528273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.
    Gore SD; Baylin S; Sugar E; Carraway H; Miller CB; Carducci M; Grever M; Galm O; Dauses T; Karp JE; Rudek MA; Zhao M; Smith BD; Manning J; Jiemjit A; Dover G; Mays A; Zwiebel J; Murgo A; Weng LJ; Herman JG
    Cancer Res; 2006 Jun; 66(12):6361-9. PubMed ID: 16778214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptional dysregulation during myeloid transformation in AML.
    Pabst T; Mueller BU
    Oncogene; 2007 Oct; 26(47):6829-37. PubMed ID: 17934489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic changes in cancer.
    Grønbaek K; Hother C; Jones PA
    APMIS; 2007 Oct; 115(10):1039-59. PubMed ID: 18042143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.